Guggenheim lowered the firm’s price target on Regeneron (REGN) to $950 from $1,200 and keeps a Buy rating on the shares. The firm, which is ...
Regeneron (REGN) announced that the U.S. Food and Drug Administration has accepted for review the resubmission of the Biologics License ...
This was the stock's second consecutive day of losses.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback
